SY
Syncom Formulations (India) Ltd (SYNCOMF)
₹23.14
Mkt cap
₹1,884 Cr
P/E ratio
22.20
P/B
5.27
Div yield
0.50%
ROE
17.60%
ROCE
24.80%
EPS (TTM)
₹1.04
Book value
₹4
52W range
10–27
Sector
Healthcare
Price history
Previous close
Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered. [1]
NSE SYNCOMFBSE 524470
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−15.82% from high₹23
₹10+126.64% from low₹27
Current
₹23.14
Prev close
₹23.96
Day
−3.42%
Price performance
1D
−3.84%
1W
+14.91%
1M
+7.71%
3M
+64.92%
6M
+106.27%
1Y
+35.69%
YTD
+60.03%
Financials
Revenue, profit & margin
P/E ratio
22.2×
SYNCOMF is 36% below the sector median of 34.6×
SYNCOMF22.2×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 59 | 62 | 63 | 73 | 87 | 101 | 127 | 148 | 117 | 121 | 115 | 134 | 125 | |
| Expenses | 53 | 56 | 57 | 64 | 76 | 90 | 112 | 131 | 101 | 103 | 93 | 113 | 99 | |
| Operating Profit | 6 | 6 | 7 | 9 | 10 | 12 | 15 | 17 | 16 | 19 | 21 | 21 | 26 | |
| OPM % | 10% | 10% | 11% | 12% | 12% | 12% | 11% | 12% | 14% | 15% | 18% | 16% | 21% | |
| Other Income | 2 | 4 | 4 | 3 | 1 | 4 | 4 | 7 | 6 | 5 | 5 | 14 | 8 | |
| Interest | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | |
| Profit before tax | 6 | 8 | 9 | 9 | 10 | 15 | 17 | 23 | 20 | 22 | 25 | 33 | 32 | |
| Tax % | 27% | 24% | 25% | 27% | 24% | 25% | 24% | 24% | 22% | 25% | 25% | 25% | 23% | |
| Net Profit | 4 | 6 | 6 | 7 | 8 | 11 | 13 | 18 | 16 | 17 | 19 | 25 | 25 | |
| EPS in Rs | 0.05 | 0.07 | 0.07 | 0.07 | 0.08 | 0.12 | 0.14 | 0.19 | 0.17 | 0.18 | 0.20 | 0.26 | 0.26 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +9.29% · closed higher next day 1 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 11 Aug '26◦ |
| Earnings day | +9.29% |
| +1 day | +4.89% |
| +5 days | +5.51% |
| +15 days | +47.21% |
| +30 days | +37.85% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202650.57%Promoter
Promoters50.57%
FIIs0.35%0.14
Public49.07%0.16
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Syncom Formul. | ₹20.04 | 22.20 | 1,884 | 0.50% | 25 | +56.62% | 125 | +6.96% | 24.78% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Announcements5
Corporate Announcement/Information Under Regulation 42 Of SEBI (LODR) Regulations, 2015 Regarding Record Date. 18 SepAnnouncement under Regulation 30 (LODR)-Newspaper Publication 8 Sep - Submission of copy of newpaper clippings of notice of 38th Annual General Meeting (AGM), Remote E-Voting, Record Date and other details.Regulation 36(1)(B) Of The SEBI (LODR) Regulations, 2015- Dispatch Of Letters To Shareholders Who Have Not Registered Their Email Addresses. 7 Sep - 38th AGM on 30 Sep 2026; annual report sent to shareholders without registered emails.Business Responsibility and Sustainability Reporting (BRSR) 7 Sep - Submitted BRSR for FY 2025-26 under SEBI LODR Regulation 34(2)(f).Submission Of The Notice Of 38Th Annual General Meeting To Be Held On Wednesday 30Th September, 2026. 7 Sep - Syncom Formulations issued notice of 38th AGM on 30 September 2026 via VC/OAVM.